Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 1,908 citations

Clonal selection and learning in the antibody system

1996 • 1,710 citations

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

2000 • 1,497 citations

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

1993 • 1,227 citations

Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin

2002 • 1,221 citations

Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

1998 • 931 citations

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

2004 • 593 citations

PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

2001 • 563 citations

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

2002 • 557 citations

Bioequivalence and the immunogenicity of biopharmaceuticals

2002 • 524 citations

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

2001 • 471 citations

Randomized controlled trial of interferon- beta-1a in secondary progressive MS

2001 • 468 citations

Randomized controlled trial of interferon-beta-1a in secondary progressive MS

2001 • 461 citations

Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.

1996 • 451 citations

Development and Selection of T Cells: Facts and Puzzles

1995 • 450 citations

Pure Red-Cell Aplasia and Epoetin Therapy

2004 • 432 citations

Interferon beta-1b in secondary progressive MS

2004 • 422 citations

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

2003 • 370 citations

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

1996 • 361 citations

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998 • 332 citations

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1988 • 251 citations

A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

2002 • 224 citations

Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

2000 • 223 citations

Immunogenicity of biopharmaceuticals

2006 • 206 citations

Evidence of interferon β-1a dose response in relapsing-remitting MS

1999 • 201 citations

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

2005 • 196 citations

Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients

2003 • 173 citations

Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity

2005 • 165 citations

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory

2002 • 149 citations

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b

1999 • 135 citations

Selection events operating at various stages in B cell development

2001 • 133 citations

The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction Unit

2001 • 119 citations

Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b

2003 • 108 citations

Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA

2003 • 102 citations

Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

2000 • 96 citations

Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis

2002 • 93 citations

The clinical impact of interferon beta antibodies in relapsing-remitting MS

2004 • 93 citations

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

2003 • 88 citations

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

2004 • 86 citations

A comparative study of the relative bioavailability of different interferon beta preparations

2000 • 86 citations

Current Disease-Modifying Therapies in Multiple Sclerosis

2003 • 82 citations

Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope

2004 • 80 citations

Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients

2002 • 78 citations

Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive

1998 • 74 citations

Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity

2003 • 72 citations

Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPs

2004 • 68 citations

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

2001 • 62 citations

ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β

1999 • 60 citations

Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

2000 • 60 citations

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity

2004 • 57 citations

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis

2004 • 55 citations

An improved ELISA for screening for neutralizing anti-IFN-β antibodies in MS patients

2003 • 53 citations

Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.

1991 • 45 citations

Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.

1989 • 43 citations

Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping.

1991 • 36 citations

Epitope Specificity of Neutralizing Antibodies Against IFN-β

2004 • 28 citations

Anti-IFNβ antibodies in IFNβ-treated MS patients

2003 • 26 citations

Neutralizing anti‐interferon‐α antibodies and response to treatment in patients with Ph⁺ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon‐α

1996 • 25 citations

Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

2003 • 24 citations

The measurement of antibodies binding to IFNβ in MS patients treated with IFNβ

2003 • 19 citations

Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment

2003 • 16 citations

Statistical approaches to assessing the effects of neutralizing antibodies

2003 • 13 citations

Chemical Mutagenesis of Human Interferon-β: Construction, Expression inE. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations

1987 • 10 citations

Immunogenicity of biopharmaceuticals. The European perspective.

2003 • 6 citations

Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis

2003 • 5 citations